Kantoff, Philip W.

Cancer nanomedicine: progress, challenges and opportunities

Shi, J., Kantoff, P. W., Wooster, R., & Farokhzad, O. C. (2017) · Nature Reviews Cancer

Nanoparticle-Based Drug DeliveryNanoplatforms for cancer theranostics

Cited by 5,873

Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer

Kantoff, P. W., Higano, C. S., Shore, N. D., Berger, E. R., Small, E. J., Penson, D. F., Redfern, C. H., Ferrari, A. C., Dreicer, R., Sims, R. B., et al. (2010) · New England Journal of Medicine

Prostate Cancer Treatment and ResearchImmunotherapy and Immune Responses

Cited by 5,572

Integrative Clinical Genomics of Advanced Prostate Cancer

Robinson, D., Van Allen, E. M., Wu, Y.-M., Schultz, N., Lonigro, R. J., Mosquera, J.-M., Montgomery, B., Taplin, M.-E., Pritchard, C. C., Attard, G., et al. (2015) · Cell

Prostate Cancer Treatment and ResearchCancer Genomics and Diagnostics

Cited by 3,645

Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer

Pritchard, C. C., Mateo, J., Walsh, M. F., De Sarkar, N., Abida, W., Beltran, H., Garofalo, A., Gulati, R., Carreira, S., Eeles, R., et al. (2016) · New England Journal of Medicine

BRCA gene mutations in cancerGenetic factors in colorectal cancer

Cited by 1,680

Genomic correlates of clinical outcome in advanced prostate cancer

Abida, W., Cyrta, J., Heller, G., Prandi, D., Armenia, J., Coleman, I., Cieslik, M., Benelli, M., Robinson, D., Van Allen, E. M., et al. (2019) · Proceedings of the National Academy of Sciences

Prostate Cancer Treatment and ResearchChromatin Remodeling and Cancer

Cited by 1,372

Changes in body composition during androgen deprivation therapy for prostate cancer

Smith, M. R., Finkelstein, J. S., McGovern, F. J., Zietman, A. L., Fallon, M. A., Schoenfeld, D. A., & Kantoff, P. W. (2002) · The Journal of Clinical Endocrinology & Metabolism

Prostate Cancer Treatment and ResearchNutrition and Health in Aging

Cited by 697

Analysis of the Prevalence of Microsatellite Instability in Prostate Cancer and Response to Immune Checkpoint Blockade

Abida, W., Cheng, M. L., Armenia, J., Middha, S., Autio, K. A., Vargas, H. A., Rathkopf, D., Morris, M. J., Danila, D. C., Slovin, S. F., et al. (2019) · JAMA Oncology

Cancer Immunotherapy and BiomarkersGenetic factors in colorectal cancer

Cited by 667

Prospective Genomic Profiling of Prostate Cancer Across Disease States Reveals Germline and Somatic Alterations That May Affect Clinical Decision Making

Abida, W., Armenia, J., Gopalan, A., Brennan, R., Walsh, M., Barron, D., Danila, D., Rathkopf, D., Morris, M., Slovin, S., et al. (2017) · JCO Precision Oncology

Prostate Cancer Treatment and ResearchCancer Genomics and Diagnostics

Cited by 541

Influence of Androgen Suppression Therapy for Prostate Cancer on the Frequency and Timing of Fatal Myocardial Infarctions

D'Amico, A. V., Denham, J. W., Crook, J., Chen, M.-H., Goldhaber, S. Z., Lamb, D. S., Joseph, D., Tai, K.-H., Malone, S., Ludgate, C., et al. (2007) · Journal of Clinical Oncology

Hormonal and reproductive studiesProstate Cancer Treatment and Research

Cited by 501

The androgen receptor cistrome is extensively reprogrammed in human prostate tumorigenesis

Pomerantz, M. M., Li, F., Takeda, D. Y., Lenci, R., Chonkar, A., Chabot, M., Cejas, P., Vazquez, F., Cook, J., Shivdasani, R. A., et al. (2015) · Nature Genetics

Prostate Cancer Treatment and ResearchChromatin Remodeling and Cancer

Cited by 470

Institutional implementation of clinical tumor profiling on an unselected cancer population

Sholl, L. M., Do, K., Shivdasani, P., Cerami, E., Dubuc, A. M., Kuo, F. C., Garcia, E. P., Jia, Y., Davineni, P., Abo, R. P., et al. (2016) · JCI Insight

Cancer Genomics and DiagnosticsGenomics and Rare Diseases

Cited by 450

Update on systemic prostate cancer therapies: management of metastatic castration-resistant prostate cancer in the era of precision oncology

Nuhn, P., De Bono, J. S., Fizazi, K., Freedland, S. J., Grilli, M., Kantoff, P. W., Sonpavde, G., Sternberg, C. N., Yegnasubramanian, S., & Antonarakis, E. S. (2019) · European Urology

Prostate Cancer Treatment and ResearchProstate Cancer Diagnosis and Treatment

Cited by 437

Enhancer RNAs participate in androgen receptor-driven looping that selectively enhances gene activation

Hsieh, C.-L., Fei, T., Chen, Y., Li, T., Gao, Y., Wang, X., Sun, T., Sweeney, C. J., Lee, G.-S. M., Chen, S., et al. (2014) · Proceedings of the National Academy of Sciences

Genomics and Chromatin DynamicsProstate Cancer Treatment and Research

Cited by 398

Phase I Clinical Trial of the CYP17 Inhibitor Abiraterone Acetate Demonstrating Clinical Activity in Patients With Castration-Resistant Prostate Cancer Who Received Prior Ketoconazole Therapy

Ryan, C. J., Smith, M. R., Fong, L., Rosenberg, J. E., Kantoff, P., Raynaud, F., Martins, V., Lee, G., Kheoh, T., Kim, J., et al. (2010) · Journal of Clinical Oncology

Prostate Cancer Treatment and ResearchBone health and treatments

Cited by 396

Enhancing tumor cell response to chemotherapy through nanoparticle-mediated codelivery of siRNA and cisplatin prodrug

Xu, X., Xie, K., Zhang, X.-Q., Pridgen, E. M., Park, G. Y., Cui, D. S., Shi, J., Wu, J., Kantoff, P. W., Lippard, S. J., et al. (2013) · Proceedings of the National Academy of Sciences

RNA Interference and Gene DeliveryNanoparticle-Based Drug Delivery

Cited by 340

Restoration of tumour-growth suppression in vivo via systemic nanoparticle-mediated delivery of PTEN mRNA

Islam, M. A., Xu, Y., Tao, W., Ubellacker, J. M., Lim, M., Aum, D., Lee, G. Y., Zhou, K., Zope, H., Yu, M., et al. (2018) · Nature Biomedical Engineering

RNA Interference and Gene DeliveryNanoparticle-Based Drug Delivery

Cited by 339

Modification of BRCA1-associated breast cancer risk by the polymorphic androgen-receptor CAG repeat.

Rebbeck, T. R., Kantoff, P. W., Krithivas, K., Neuhausen, S., Blackwood, M. A., Godwin, A. K., Daly, M. B., Narod, S. A., Garber, J. E., Lynch, H. T., et al. (1999) · The American Journal of Human Genetics

BRCA gene mutations in cancerGenetic factors in colorectal cancer

Cited by 252

Development and Clinical Validation of an In Situ Biopsy-Based Multimarker Assay for Risk Stratification in Prostate Cancer

Blume-Jensen, P., Berman, D. M., Rimm, D. L., Shipitsin, M., Putzi, M., Nifong, T. P., Small, C., Choudhury, S., Capela, T., Coupal, L., et al. (2015) · Clinical Cancer Research

Prostate Cancer Diagnosis and TreatmentProstate Cancer Treatment and Research

Cited by 179

High-fat diet fuels prostate cancer progression by rewiring the metabolome and amplifying the MYC program

Labbé, D. P., Zadra, G., Yang, M., Reyes, J. M., Lin, C. Y., Cacciatore, S., Ebot, E. M., Creech, A. L., Giunchi, F., Fiorentino, M., et al. (2019) · Nature Communications

Cancer, Lipids, and MetabolismProstate Cancer Treatment and Research

Cited by 174

A prognostic index model for predicting overall survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate after docetaxel

Chi, K. N., Kheoh, T., Ryan, C. J., Molina, A., Bellmunt, J., Vogelzang, N. J., Rathkopf, D. E., Fizazi, K., Kantoff, P. W., Li, J., et al. (2016) · Annals of Oncology

Prostate Cancer Treatment and ResearchBone health and treatments

Cited by 167

SLCO2B1 and SLCO1B3 May Determine Time to Progression for Patients Receiving Androgen Deprivation Therapy for Prostate Cancer

Yang, M., Xie, W., Mostaghel, E., Nakabayashi, M., Werner, L., Sun, T., Pomerantz, M., Freedman, M., Ross, R., Regan, M., et al. (2011) · Journal of Clinical Oncology

Prostate Cancer Treatment and ResearchPharmacogenetics and Drug Metabolism

Cited by 159

A Novel Mechanism Driving Poor-Prognosis Prostate Cancer: Overexpression of the DNA Repair Gene, Ribonucleotide Reductase Small Subunit M2 (RRM2)

Mazzu, Y. Z., Armenia, J., Chakraborty, G., Yoshikawa, Y., Coggins, S. A., Nandakumar, S., Gerke, T. A., Pomerantz, M. M., Qiu, X., Zhao, H., et al. (2019) · Clinical Cancer Research

Prostate Cancer Treatment and ResearchDNA Repair Mechanisms

Cited by 156

Racial differences in genomic profiling of prostate cancer

Mahal, B. A., Alshalalfa, M., Kensler, K. H., Chowdhury-Paulino, I., Kantoff, P., Mucci, L. A., Schaeffer, E. M., Spratt, D., Yamoah, K., Nguyen, P. L., et al. (2020) · New England Journal of Medicine

Prostate Cancer Treatment and ResearchCancer Genomics and Diagnostics

Cited by 126

Phase 1 study of PSMA ADC, an antibody‐drug conjugate targeting prostate‐specific membrane antigen, in chemotherapy‐refractory prostate cancer

Petrylak, D. P., Kantoff, P., Vogelzang, N. J., Mega, A., Fleming, M. T., Stephenson, J. J., Frank, R., Shore, N. D., Dreicer, R., McClay, E. F., et al. (2019) · The Prostate

Prostate Cancer Treatment and ResearchProstate Cancer Diagnosis and Treatment

Cited by 84